How effective is post-treatment surveillance for lobular carcinoma in situ?

Lobular carcinoma in situ is a breast finding associated with increased future breast cancer risk rather than an invasive cancer itself. Follow-up provides a structured opportunity to review breast changes, family history, previous biopsy information, imaging, and options for reducing risk. The plan may involve clinical review and breast imaging selected for your circumstances.

Monitoring does not remove future risk or guarantee that a new breast problem will be prevented. It also does not mean that every new lump is cancer. A clinician assesses any change using its features, your history, and appropriate testing.

Attend the breast assessments recommended for you and keep copies of imaging or biopsy information when available. Tell your team about a new lump, nipple change, skin dimpling, discharge, or persistent focal discomfort. Discuss medicines used for risk reduction, their possible effects, and whether they fit your health history.

Ask how to check for changes without becoming alarmed by normal breast variation. Keep your family history updated, especially if a close relative develops breast or ovarian cancer, because this may affect the advice you receive.

Arrange prompt clinical advice for a new or persistent lump, nipple inversion, bloody discharge, skin dimpling, a change in breast shape, or a swollen area in the armpit. Seek urgent help for severe chest symptoms or rapidly worsening illness. A breast change needs assessment; it does not by itself show that cancer is present.

What surveillance schedule suits my breast history? Which imaging is recommended and why? Would risk-reducing medicine be appropriate for me? How should family history affect my plan? Which breast changes should I report before my next visit?